Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials

References

• Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44: S125–S150.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association 11. Microvascular complications and foot care: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S151–S167.
   PubMed Web of Science ®Google Scholar
• Sims-Robinson C, Kim B, Rosko A, et al. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol. 2010;6(10):551–559.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–221.
   PubMed Web of Science ®Google Scholar
• Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715–748.
   PubMed Web of Science ®Google Scholar
• Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625.
   PubMed Web of Science ®Google Scholar
• Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med. 1996;74(6):297–312.
   PubMed Web of Science ®Google Scholar
• Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27(2):120–139.
   PubMed Web of Science ®Google Scholar
• Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993;362(6422):709–715.
   PubMed Web of Science ®Google Scholar
• Yan LL, Zaher HS. How do cells cope with RNA damage and its consequences? J Biol Chem. 2019;294(41):15158–15171.
   PubMed Web of Science ®Google Scholar
• Poulsen HE, Nadal LL, Broedbaek K, et al. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochim Biophys Acta. 2014;1840(2):801–808.
   PubMed Web of Science ®Google Scholar
• Liu X, Gan W, Zou Y, et al. Elevated levels of urinary markers of oxidative DNA and RNA damage in type 2 diabetes with complications. Oxid Med Cell Longev. 2016;2016:4323198.
   PubMed Web of Science ®Google Scholar
• Broedbaek K, Siersma V, Henriksen T, et al. Association Between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes: a population-based cohort study. Diabetes Care. 2013;36(3):669–676.
   PubMed Web of Science ®Google Scholar
• Broedbaek K, Køster-Rasmussen R, Siersma V, et al. Urinary albumin and 8-oxo-7, 8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes – A comparative study of two markers to identify high risk patients. Redox Biol. 2017;13:363–369.
   PubMed Web of Science ®Google Scholar
• Kjær LK, Cejvanovic V, Henriksen T, et al. Cardiovascular and all-cause mortality risk associated with urinary excretion of 8-oxoGuo, a biomarker for RNA oxidation, in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2017;40(12):1771–1778.
   PubMed Web of Science ®Google Scholar
• Larsen EL, Weimann A, Poulsen HE. Interventions targeted at oxidatively generated modifications of nucleic acids focused on urine and plasma markers. Free Radic Biol Med. 2019;145:256–283.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Chock PB, Stadtman ER. Oxidized messenger RNA induces translation errors. Proc Natl Acad Sci U S A. 2007;104(1):66–71.
   PubMed Web of Science ®Google Scholar
• Wang J-X, Gao J, Ding S-L, et al. Oxidative modification of miR-184 enables it to target bcl-xL and bcl-w. Mol Cell. 2015;59(1):50–61.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761–772.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose Co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9(11):e112394.
   PubMed Web of Science ®Google Scholar
• Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–385.
   PubMed Web of Science ®Google Scholar
• Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139(17):1985–1987.
   PubMed Web of Science ®Google Scholar
• Meneghini R. Iron homeostasis, oxidative stress, and DNA damage, free. Free Radic Biol Med. 1997;23(5):783–792.
   PubMed Web of Science ®Google Scholar
• Larsen EL, Cejvanovic V, Kjær LK, et al. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open. 2017;7(5):e014728.
   PubMed Web of Science ®Google Scholar
• Rasmussen ST, Andersen JT, Nielsen TK, et al. Simvastatin and oxidative stress in humans: a randomized, double-blinded, placebo-controlled clinical trial. Redox Biol. 2016;9:32–38.
   PubMed Web of Science ®Google Scholar
• Lykkesfeldt J. Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin. Chem. 2001;47(9):1725–1727.
   PubMed Web of Science ®Google Scholar
• Eickhoff MK, Olsen FJ, Frimodt-Møller M, et al. Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial. J Diabetes Complications. 2020;34(7):107590.
   PubMed Web of Science ®Google Scholar
• Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21(7):363–383.
   PubMed Web of Science ®Google Scholar
• van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 2020;97(1):202–212.
   PubMed Web of Science ®Google Scholar
• Larsen EL, Cejvanovic V, Kjaer LK, et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. Br J Clin Pharmacol. 2017;83(8):1643–1653.
   PubMed Web of Science ®Google Scholar
• Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.
   PubMed Web of Science ®Google Scholar
• Van Steenbergen A, Balteau M, Ginion A, et al. Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart. Sci Rep. 2017;7:41166.
   PubMed Web of Science ®Google Scholar
• Sivalingam S, Larsen EL, van Raalte DH, et al. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Sci Rep. 2021;11(1):10624.
   PubMed Web of Science ®Google Scholar
• Skytte MJ, Samkani A, Astrup A, et al. Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. Scand J Clin Lab Invest. 2020;80(5):401–407.
   PubMed Web of Science ®Google Scholar
• Poulsen HE, Weimann A, Henriksen T, et al. Oxidatively generated modifications to nucleic acids in vivo: measurement in urine and plasma. Free Radic Biol Med. 2019;145:336–341.
   PubMed Web of Science ®Google Scholar
• Broedbaek K, Poulsen HE, Weimann A, et al. Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med. 2009;47(8):1230–1233.
   PubMed Web of Science ®Google Scholar
• Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J. Clin. Endocrinol. Metab. 2020;105(4):e1056–e1063.
   Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol. 2015;14:11–11.
   PubMed Web of Science ®Google Scholar
• Lambadiari V, Thymis J, Kouretas D, et al. Effects of a 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on oxidant and antioxidant biomarkers in patients with type 2 diabetes. Antioxid.z. 2021;10(9):1379.
   Web of Science ®Google Scholar
• Grew IS, Cejvanovic V, Broedbaek K, et al. Diurnal variation of urinary markers of nucleic acid oxidation. Scand J Clin Lab Invest. 2014;74(4):336–343.
   PubMed Web of Science ®Google Scholar